Merck, Moderna Expand Phase 3 Keytruda/V940 Combo Work
December 11 2023 - 7:41AM
Dow Jones News
By Colin Kellaher
Merck and Moderna have launched a second late-stage study of the
combination of Merck's blockbuster cancer drug Keytruda with V940,
an individualized neoantigen therapy they are jointly
developing.
The companies on Monday said the Phase 3 randomized clinical
trial will evaluate the combination as adjuvant treatment in
patients with certain types of resected non-small cell lung
cancer.
Merck and Moderna, which previously launched a Phase 3 study of
the combination in patients with resected high-risk melanoma, said
they plan to continue expansion of the clinical development program
for V940 to additional tumor types.
Lung cancer is the leading cause of cancer death around the
world, with non-small cell lung cancer accounting for more than 80%
of all cases.
Keytruda is a cancer drug that harnesses a patient's immune
system to fight tumors, while individualized neoantigen therapies
such as V940 are designed to train and activate an antitumor immune
response by generating specific T-cell responses based on the
unique mutational signature of a patient's tumor.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 11, 2023 07:26 ET (12:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2023 to Dec 2024
